Treatment of type III hyperlipoproteinemia with gemfibrozil to retard progression of coronary artery disease

Am Heart J. 1988 Jul;116(1 Pt 1):85-90. doi: 10.1016/0002-8703(88)90253-0.

Abstract

Eight type III hyperlipoproteinemic (type III HLP), homozygous E 2/2 patients were enrolled in two periods of long-term diet-gemfibrozil treatment. The combined therapy resulted in highly significant decreases in their low-density lipoprotein cholesterol, very-low density lipoprotein cholesterol, very-low density lipoprotein triglycerides, and increases in their high-density lipoprotein cholesterol during the first treatment period of 24 to 28 months. Type III HLP reasserted itself following an 8-week interruption of gemfibrozil therapy. Resumption of gemfibrozil therapy again lowered the high lipid-lipoprotein concentrations of these patients toward normal. Tuboeruptive xanthomata, palmar xanthoma, and xanthoma striata palmare subsided with treatment. Follow-up coronary arteriograms performed 2.5 to 3.0 years after initiation of diet-drug treatment showed stabilization of coronary arterial lesions, which was associated with improvement in exercise tolerance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Combined Modality Therapy
  • Coronary Disease / etiology
  • Coronary Disease / prevention & control*
  • Drug Evaluation
  • Exercise Test
  • Female
  • Gemfibrozil
  • Hand Dermatoses / etiology
  • Hand Dermatoses / prevention & control
  • Humans
  • Hyperlipoproteinemia Type III / complications
  • Hyperlipoproteinemia Type III / diet therapy
  • Hyperlipoproteinemia Type III / drug therapy*
  • Hypolipidemic Agents / adverse effects
  • Hypolipidemic Agents / therapeutic use*
  • Lipids / blood
  • Lipoproteins / blood
  • Male
  • Middle Aged
  • Pentanoic Acids / adverse effects
  • Pentanoic Acids / therapeutic use*
  • Valerates / therapeutic use*
  • Xanthomatosis / etiology
  • Xanthomatosis / prevention & control

Substances

  • Hypolipidemic Agents
  • Lipids
  • Lipoproteins
  • Pentanoic Acids
  • Valerates
  • Gemfibrozil